EP 1049665 A1 20001108 - VLA-4 ANTAGONISTS
Title (en)
VLA-4 ANTAGONISTS
Title (de)
VLA-4-ANTAGONISTEN
Title (fr)
ANTAGONISTES D'ANTIGENE-4 D'ACTIVATION TRES TARDIVE (VLA-4)
Publication
Application
Priority
- EP 9900384 W 19990121
- US 1233698 A 19980123
- US 11072398 P 19981203
Abstract (en)
[origin: WO9937605A1] Compounds of formula (I) and their pharmaceutically acceptable salts are VLA-4 antagonists. They are useful in inhibiting cell adhesion and in the therapeutic or prophylactic treatment of inflammatory and autoimmune diseases, particularly inflammatory airways diseases. They are particularly useful in reducing post-surgical inflammation, especially that resulting from transplant surgery.
IPC 1-7
IPC 8 full level
A61K 31/16 (2006.01); A61K 31/167 (2006.01); A61K 31/17 (2006.01); C07C 237/22 (2006.01); C07C 275/42 (2006.01)
CPC (source: EP KR)
A61K 31/167 (2013.01 - EP); A61P 37/06 (2017.12 - EP); C07C 237/22 (2013.01 - EP); C07C 275/42 (2013.01 - EP KR); C07B 2200/07 (2013.01 - EP)
Citation (search report)
See references of WO 9937605A1
Designated contracting state (EPC)
AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE
DOCDB simple family (publication)
WO 9937605 A1 19990729; AU 2829299 A 19990809; AU 746174 B2 20020418; BR 9907733 A 20001017; CA 2318639 A1 19990729; CN 1294576 A 20010509; EE 200000428 A 20011217; EP 1049665 A1 20001108; HU P0100336 A2 20010730; HU P0100336 A3 20021128; ID 26665 A 20010125; IL 137329 A0 20010724; JP 2002501039 A 20020115; JP 4564654 B2 20101020; KR 20010034317 A 20010425; NO 20003694 D0 20000719; NO 20003694 L 20000920
DOCDB simple family (application)
EP 9900384 W 19990121; AU 2829299 A 19990121; BR 9907733 A 19990121; CA 2318639 A 19990121; CN 99803780 A 19990121; EE P200000428 A 19990121; EP 99908811 A 19990121; HU P0100336 A 19990121; ID 20001404 A 19990121; IL 13732999 A 19990121; JP 2000528529 A 19990121; KR 20007008039 A 20000722; NO 20003694 A 20000719